- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- Analysis
- Focus Articles
- Related Articles1 new
- Instablogs
- StockTalks
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
PPH Market Currents
more »
-
April 30 Pure pharmaceuticals players, like AstraZeneca (AZN), Bristol-Myers (BMY) and Eli Lilly (LLY), are likely to face higher earnings pressure over the next three years than more-diversified firms like J&J (JNJ) or Bayer (BAYRY.PK), says Fitch. Cash-rich pure-players with a relatively weak R&D pipeline, like AZN, may be tempted to go on buying sprees.
Comment![Healthcare, Quick Ideas]
ETF Stats
- Expense Ratio: 0.35%
- Average Bid Ask Ratio:
- Tracking Error:
- Concentration Risk:
- Capital Gains Dist. %:
- Number of Securities: 25
- Dividend Amount:
- Dividend Date:
For overall rating and ranking versus other ETFs get a free trial to XTF Premium
PPH in Focus
more »
PPH Related Articles
more »
PPH News
more »
-
at MarketWatch.com (Aug 28, 2011)
PPH Press Releases and Filings
more »
Currently, there are no press releases or filings on PPH.
PPH Cramer
more »
-
Wed, Jul 9, 2008
-
Wed, Aug 2, 2006
PPH Instablog posts
more »
PPH vs. ETF Alternatives
PPH Description
The Market Vectors® Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors US Listed Pharmaceutical 25 Index (MVPPHTR). The Index is a rules-based index intended to track the overall performance of 25 of the largest U.S. listed, publicly traded pharmaceutical companies.
See more details on sponsor's website
See more details on sponsor's website
Sector: Healthcare
Country: United States
Key Info
- In Your Portfolio: A Guide to Sector ETFs, A Guide to Healthcare, Pharma and Biotech ETFs
- Asset Class Performance: Themes & Subsectors, Sectors